Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AAV2sFLT 01 - Applied Genetic Technologies

Drug Profile

AAV2sFLT 01 - Applied Genetic Technologies

Alternative Names: AAV2-sFLT01; age-related macular degeneration gene therapy - Applied Genetic Technologies; anti vascular endothelial growth factor (VEGF) gene therapy - Applied Genetic Technologies; GZ-402663; sFLT-01

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Applied Genetic Technologies Corporation; Genzyme Corporation
  • Developer Applied Genetic Technologies Corporation; Genzyme Corporation; JDRF
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene transference; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Age-related macular degeneration
  • Discontinued Diabetic retinopathy

Most Recent Events

  • 01 Jul 2018 Phase I development in Age-related macular degeneration is ongoing in USA (Intravitreous) (NCT01024998)
  • 01 Jul 2018 Genzyme completes a phase I trial in Age-related macular degeneration in USA (Intravitreous) (NCT01024998)
  • 16 Jul 2013 Genzyme enters cross-license agreement for use of Asklepios BioPharmaceutical's Duplex gene therapy vector technology for Genzyme's internal product development research (including AAV2sFLT-01 for age-related macular degeneration) and external sublicensing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top